¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

´ëÇÑ ÆÄŲ½¼º´ ¹× ÀÌ»ó¿îµ¿Áúȯ ÇÐȸ(KMDS) 2024 Ãá°èº¸¼ö±³À° (2ÀÏÂ÷) : 2024-04-14

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 

´ëÇÑ ÆÄŲ½¼º´ ¹× ÀÌ»ó¿îµ¿Áúȯ ÇÐȸ(KMDS) 2024 Ãá°èº¸¼ö±³À° (2ÀÏÂ÷) : 2024-04-14
±³À°ÀÏÀÚ : 2024-04-14
±³À°Àå¼Ò : »ïÁ¤È£ÅÚ ¶óº¥´õȦ

±³À°ÁÖÁ¦ : ´ëÇÑ ÆÄŲ½¼º´ ¹× ÀÌ»ó¿îµ¿Áúȯ ÇÐȸ(KMDS) 2024 Ãá°èº¸¼ö±³À° (2ÀÏÂ÷)

ÁÖÃÖ±â°ü : ´ëÇÑÆÄŲ½¼º´¹×ÀÌ»ó¿îµ¿ÁúȯÇÐȸ
´ã´çÀÚ : Ãֹ̼Ò
¿¬¶ôó : 02-6395-2876  

À̸ÞÀÏ : movement@kmds.or.kr

±³À°Á¾·ù : ½Å°æ°ú

Âü¼®¿¹»óÀÎ : 100¸í
Èñ¸ÁÆòÁ¡ : 3Á¡

Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 3 ½Ã°£ 50ºÐ

¼¼ºÎ¼ö°­·á : 120,000¿ø  

ºñ°í »çÀüµî·Ï(Á¤È¸¿ø 50,000¿ø, ÁØȸ¿ø 30,000¿ø, ºñȸ¿ø Àü¹®ÀÇ 100,000¿ø, ºñȸ¿ø Àü°øÀÇ 40,000¿ø) ÇöÀåµî·Ï(Á¤È¸¿ø 60,000¿ø, ÁØȸ¿ø 40,000¿ø, ºñȸ¿ø Àü¹®ÀÇ 120,000¿ø, ºñȸ¿ø Àü°øÀÇ 50,000¿ø)


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±âŸ 04¿ù 14ÀÏ »ïÁ¤È£ÅÚ ¶óº¥´õȦ 09:00~10:40 Session 1. Diagnosis and Management of Miscellaneous Movement Disorders °­¼®À±(ÇѸ²ÀÇ´ë)

±³À°½Ã°£ 04¿ù 14ÀÏ »ïÁ¤È£ÅÚ ¶óº¥´õȦ 09:00~09:30 Movement Disorders in In-patient & Emergency Settings ¹Úµ¿±Ô(¾ÆÁÖÀÇ´ë)

±³À°½Ã°£ 04¿ù 14ÀÏ »ïÁ¤È£ÅÚ ¶óº¥´õȦ 09:30~10:00 Diagnosis and Management of Tardive Syndromes ¹é°æ¿ø(°í·ÁÀÇ´ë)

±³À°½Ã°£ 04¿ù 14ÀÏ »ïÁ¤È£ÅÚ ¶óº¥´õȦ 10:00~10:30 Functional Movement Disorders ¹ÚÁ¤ÀÌ(µ¿±¹ÀÇ´ë)

Åä·Ð 04¿ù 14ÀÏ »ïÁ¤È£ÅÚ ¶óº¥´õȦ 10:30~10:40 Q&A °­¼®À±(ÇѸ²ÀÇ´ë)

±âŸ 04¿ù 14ÀÏ »ïÁ¤È£ÅÚ ¶óº¥´õȦ 10:50~12:10 Session 2. Lessons from Historic Clinical Trials ¹ÚÁ¤È£(¼øõÇâÀÇ´ë)

±³À°½Ã°£ 04¿ù 14ÀÏ »ïÁ¤È£ÅÚ ¶óº¥´õȦ 10:50~11:30 Levodopa and Dopamine Agonists À¯´Þ¶ó(°æÈñÀÇ´ë)

±³À°½Ã°£ 04¿ù 14ÀÏ »ïÁ¤È£ÅÚ ¶óº¥´õȦ 11:30~12:10 MAO-B Inhibitors and COMT Inhibitors Á¤¼®Á¾(¿¬¼¼ÀÇ´ë)

±âŸ 04¿ù 14ÀÏ »ïÁ¤È£ÅÚ ¶óº¥´õȦ 12:10~13:00 Session 3. Case-based Learning - Panels Discussion Á¶¼º¾ç(¿ï»êÀÇ´ë)

Åä·Ð 04¿ù 14ÀÏ »ïÁ¤È£ÅÚ ¶óº¥´õȦ 12:10~13:00 How to Optimize the Dopaminergic Treatment of Parkinson¡¯s Disease? °í¼º¹ü/¹ÚÁ¤È£/À¯´Þ¶ó/Á¤¼®Á¾(°í·ÁÀÇ´ë/¼øõÇâÀÇ´ë/°æÈñÀÇ´ë/¿¬¼¼ÀÇ´ë)

 

ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ´ëÇÑ ÆÄŲ½¼º´ ¹× ÀÌ»ó¿îµ¿Áúȯ ÇÐȸ(KMDS) 2024 Ãá°èº¸¼ö±³À° (2ÀÏÂ÷) : 2024-04-14""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û (¿Â¶óÀÎ)2024³â Á¦8Â÷ ´ëÇѼö¸éÈ£ÈíÇÐȸ ¼ö¸é´Ù¿ø°Ë»ç ±âº»±³À°°­Á : 2024-04-14
´ÙÀ½±Û ´ëÇѾ๰¿µ¾çÀÇÇÐȸ 2024³â ±¤ÁÖÇмú´ëȸ : 2024-04-14
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20619 °æ³² »ï¼ºÃ¢¿øº´¿ø (¿Â¶óÀÎ)»ï¼ºÃ¢¿ø Ambulatory Pediatrics 2024 : 2024-06-29 0 130 2024-04-30
20618 °æºÏ Á¦8Â÷ ´ëÇѸðüžÆÀÇÇÐȸ °³¿øÀǸ¦ À§ÇÑ ¿¬¼ö°­ÁÂ(¿µ³²) : 2024-06-29 0 50 2024-04-30
20617 ¼­¿ï °Ç±¹´ëÇб³º´¿ø 2024 KUMC Precision Medicine Lung Cancer Conference : 2024-06-28 0 44 2024-04-30
20616 ¼­¿ï 2024 ´ëÇÑÇ÷¾×ÇÐȸ ÀûÇ÷±¸Áúȯ¿¬±¸ ½ÉÆ÷Áö¾ö : 2024-06-28 0 59 2024-04-30
20615 ¼­¿ï (¿Â¶óÀÎ)À̺ñÀÎÈÄ°ú Áö¿ªÀÇ»çÁý´ãȸ-°³¿ø°¡¿¡¼­ ÀÇ·ÚÇÑ µÎ°æºÎ¾Ï ȯÀÚÀÇ Ä¡·á ¹× °æ°ú : 2024-06-27 0 47 2024-04-30
20614 ¼­¿ï 2024³â ´ëÇÑÈäºÎ¿µ»óÀÇÇÐȸ ¿¬¼ö°­Á : 2024-06-23 0 46 2024-04-30
20613 ´ë±¸ ´ëÇѽºÆ÷Ã÷ÀÇÇÐȸ Sports Medicine Symposium 2024 in Daegu : 2024-06-23 0 72 2024-04-29
20612 ¼­¿ï 2024³â ´ëÇÑ°ñ´ë»çÇÐȸ Á¦12Â÷ Clinical Densitometry Course : 2024-06-23 0 67 2024-04-29
20611 ¼­¿ï 2024³â ü°èÀû ¹®Çå°íÂû(¸ÞŸºÐ¼®) ³í¹®Ãâ°£ ¿öÅ©¼¥ 1Â÷(2ÀÏÂ÷) : 2024-06-22 0 59 2024-04-29
20610 ¼­¿ï ¼­¿ï¾Æ»êº´¿ø (¿Â¶óÀÎ) 6¿ù 21ÀÏ ±Ý¿äÁý´ãȸ(ÀÌ°ü ÁúȯÀÇ Áø´Ü°ú Ä¡·á) : 2024-06-21 0 63 2024-04-29
20609 °æ±â ¾È»ê ¹× ½ÃÈ­Áö¿ª À̺ñÀÎÈÄ°ú Àǻ縦 À§ÇÑ Áý´ãȸ(¾È¸é¸¶ºñ) : 2024-06-21 0 43 2024-04-29
20608 ¼­¿ï 2024³â ü°èÀû ¹®Çå°íÂû(¸ÞŸºÐ¼®) ³í¹®Ãâ°£ ¿öÅ©¼¥ 1Â÷(1ÀÏÂ÷) : 2024-06-21 0 58 2024-04-29
20607 ¼­¿ï 2024 ´ëÇÑȯ°æõ½ÄÆóÁúȯÇÐȸ Ãá°èÇмú´ëȸ : 2024-06-21 0 57 2024-04-29
20606 ¼­¿ï (¿Â¶óÀÎ)À̺ñÀÎÈÄ°ú Áö¿ªÀÇ»çÁý´ãȸ-¿Ü·¡¿¡¼­ °£´ÜÇÏ°Ô ÇÒ ¼ö ÀÖ´Â À½¼ºÄ¡·á : 2024-06-20 0 53 2024-04-29
20605 ´ë±¸ ´ëÇÑ»êºÎÀΰúÇÐȸ ´ë±¸Áöȸ ¿¬¼ö°­Á : 2024-06-20 0 47 2024-04-29
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷